Literature DB >> 26166867

Synthesis and in vitro activity of novel 2-(benzylthio)-4-chloro-5-(1,3,4-oxadiazol-2-yl)benzenesulfonamide derivatives.

Kamil Brożewicz1, Jarosław Sławiński1.   

Abstract

ABSTRACT: Two series of novel 4-chloro-2-(benzylthio)-5-(1,3,4-oxadiazol-2-yl)benzenesulfonamides and their N-aroyl derivatives have been synthesized and evaluated for in vitro anticancer activity against the full NCI-60 cell line panel. Most of the compounds exhibited antiproliferative activity. Among them a compound bearing an N-(thien-2-ylcarbonyl) moiety showed broad-spectrum activity with 50% growth inhibition (GI50) values in the range of 2.02-7.82 μM over 50 cell lines. GRAPHICAL ABSTRACT: .

Entities:  

Keywords:  2-Mercaptobenzenesulfonamides; Acylsulfonamides; Antitumor agents; Heterocycles; Phase-transfer catalysis

Year:  2012        PMID： 26166867      PMCID： PMC4494775          DOI： 10.1007/s00706-012-0732-6

Source DB:  PubMed          Journal:  Monatsh Chem        ISSN： 0026-9247            Impact factor:   1.451


  27 in total

1.  Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides.

Authors:  Franciszek Saczewski; Alessio Innocenti; Zdzisław Brzozowski; Jarosław Slawiński; Elzbieta Pomarnacka; Anita Kornicka; Andrea Scozzafava; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2006-10       Impact factor: 5.051

2.  Synthesis, molecular structure, and in vitro antitumor activity of new 4-chloro-2-mercaptobenzenesulfonamide derivatives.

Authors:  Jarosław Sławiński; Maria Gdaniec
Journal:  Eur J Med Chem       Date:  2005-04       Impact factor: 6.514

3.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

4.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

5.  Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.

Authors:  Karen L Lobb; Philip A Hipskind; James A Aikins; Enrique Alvarez; Yiu-Yin Cheung; Eileen L Considine; Alfonso De Dios; Gregory L Durst; Rafael Ferritto; Cora Sue Grossman; Deborah D Giera; Beth A Hollister; Zhongping Huang; Philip W Iversen; Kevin L Law; Tiechao Li; Ho-Shen Lin; Beatriz Lopez; Jose E Lopez; Luisa M Martin Cabrejas; Denis J McCann; Victoriano Molero; John E Reilly; Michael E Richett; Chuan Shih; Beverly Teicher; James H Wikel; Wesley T White; Mary M Mader
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

6.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Authors:  J S Lee; K Paull; M Alvarez; C Hose; A Monks; M Grever; A T Fojo; S E Bates
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.

Authors:  V G Matassa; T P Maduskuie; H S Shapiro; B Hesp; D W Snyder; D Aharony; R D Krell; R A Keith
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

9.  Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.

Authors:  Alexander Dömling; Walfrido Antuch; Barbara Beck; Vesna Schauer-Vukasinović
Journal:  Bioorg Med Chem Lett       Date:  2008-05-29       Impact factor: 2.823

10.  The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

Authors:  Scott Ackler; Michael J Mitten; Kelly Foster; Anatol Oleksijew; Marion Refici; Stephen K Tahir; Yu Xiao; Christin Tse; David J Frost; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore; Alexander R Shoemaker
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-23       Impact factor: 3.333
View more
  3 in total

1.  Synthesis of a new series of biologically interesting 6'-chloro-1',1'-dioxospiro[4H-benzo[d][1,3,7]oxadiazocine-4,3'(2'H)-[1,4,2]benzodithiazine]-2,6(1H,5H)dione derivatives.

Authors:  Zdzisław Brzozowski; Beata Żołnowska; Jarosław Sławiński
Journal:  Monatsh Chem       Date:  2013-06-11       Impact factor: 1.451

2.  Mass spectrometry based identification of geometric isomers during metabolic stability study of a new cytotoxic sulfonamide derivatives supported by quantitative structure-retention relationships.

Authors:  Mariusz Belka; Weronika Hewelt-Belka; Jarosław Sławiński; Tomasz Bączek
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

3.  Synthesis, Molecular Structure, Metabolic Stability and QSAR Studies of a Novel Series of Anticancer N-Acylbenzenesulfonamides.

Authors:  Beata Żołnowska; Jarosław Sławiński; Mariusz Belka; Tomasz Bączek; Anna Kawiak; Jarosław Chojnacki; Aneta Pogorzelska; Krzysztof Szafrański
Journal:  Molecules       Date:  2015-10-21       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.